Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar

Revista Espanola de Cardiologia

Volumn 62, Issue 12, 2009, Pages 1464.e1-1464.e58

  Galiè, Nazzareno ^a   Hoeper, Marius M ^b   Humbert, Marc ^b   Torbicki, Adam ^b   Vachiery, Jean Luc ^b   Barberá, Joan Albert ^b   Beghetti, Maurice ^b   Corris, Paul ^c   Gaine, Sean ^b   Simon Gibbs, J ^c   Gómez Sánchez, Miguel Ángel ^b   Jondeau, Guillaume ^b   Klepetko, Walter ^b   Opitz, Christian ^b   Peacock, Andrew ^c   Rubin, Lewis ^b   Zellweger, Michael ^b   Simonneau, Gerald ^b  

^a coordinador ^*  (Italy)

^b Reino Unido ^*

^c Esc de Educacion de Birmingham   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75749089972     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)73130-6     Document Type: Article

References (261)

1. Simonneau G., Robbins I., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54 (2009) S43-S54
2. Hachulla E., Gressin V., Guillevin L., Carpentier P., Diot E., Sibilia J., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 52 (2005) 3792-3800
3. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 (2006) 1023-1030
4. Peacock A.J., Murphy N.F., McMurray J.J.V., Caballero L., and Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30 (2007) 104-109
5. Duffels M.G.J., Engelfriet P.M., Berger R.M.F., Van Loon R.L.E., Hoendermis E., Vriend J.W.J., et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 120 (2007) 198-204
6. Condliffe R., Kiely D.G., Gibbs J.S., Corris P.A., Peacock A.J., Jenkins D.P., et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension patients. Am J Respir Crit Care Med 177 (2008) 1122-1127
7. Hatano S., and Strasser T. World Health Organization 1975. Primary pulmonary hypertension (1975), WHO, Geneva
8. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
9. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. Eur Respir J. 2009;doi: 10.1183/09031936.00145608.
10. Badesch B.D., Champion H.C., Gómez-Sánchez M.A., Hoeper M., Loyd J., Manes A., et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009) S55-S56
11. Naeije R., Melot C., Niset G., Delcroix M., and Wagner P.D. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. J Appl Physiol 74 (1993) 1666-1671
12. Oudiz R.J. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 28 (2007) 233-241
13. Simonneau G., Galiè N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) S5-S12
14. Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B., Schwalbe E.C., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 27 (2006) 121-132
15. Machado R., Eickelberg O., Elliott C.G., Geraci M., Hanoaka M., Loyd J., et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009) S32-S42
16. Galiè N., Manes A., Palazzini M., Negro L., Marinelli A., Gambetti S., et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 68 (2008) 1049-1066
17. Lapa M.S., Ferreira E.V., Jardim C., Martins B.C., Arakaki J.S., and Souza R. Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of São Paulo. Rev Assoc Med Bras 52 (2006) 139-143
18. Gladwin M.T., Sachdev V., Jison M.L., Shizukuda Y., Plehn J.F., Minter K., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 (2004) 886-895
19. Reiter C.D., Wang X., Tanus-Santos J.E., Hogg N., Cannon III R.O., Schechter A.N., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8 (2002) 1383-1389
20. Pietra G.G., Capron F., Stewart S., Leone O., Humbert M., Robbins I.M., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 (2004) S25-S32
21. Tuder R.M., Abman S.H., Braun T., Capron F., Stevens T., Thistlethwaite P.A., et al. Pulmonary circulation: development and pathology. J Am Coll Cardiol 54 (2009) S3-S9
22. Fedullo P.F., Auger W.R., Kerr K.M., and Rubin L.J. Chronic thromboembolic pulmonary hypertension. N Engl J Med 345 (2001) 1465-1472
23. Galiè N., and Kim N.H.S. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 (2006) 571-576
24. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) S13-S24
25. Hassoun P.M., Mouthon L., Barbera J.A., Eddahibi S., Flores S.C., Grimminger F., et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54 (2009) S10-S19
26. Morrell N., Adnot S., Archer S., Dupuis J., Jones P., MacLean M.R., et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009) S20-S31
27. Delgado J.F., Conde E., Sánchez V., López-Ríos F., Gómez- Sánchez M.A., Escribano P., et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 7 (2005) 1011-1016
28. Lang I.M. Chronic thromboembolic pulmonary hypertension- not so rare after all. N Engl J Med 350 (2004) 2236-2238
29. Gabbay E., Yeow W., and Playford D. Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography study. Am J Resp Crit Care Med 175 (2007) A713
30. Sztrymf B., Coulet F., Girerd B., Yaici A., Jais X., Sitbon O., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177 (2008) 1377-1383
31. Trembath R.C., Thomson J.R., Machado R.D., Morgan N.V., Atkinson C., Winship I., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345 (2001) 325-334
32. Ghio S., Gavazzi A., Campana C., Inserra C., Klersy C., Sebastiani R., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37 (2001) 183-188
33. Vahanian A., Baumgartner H., Bax J., Butchart E., Dion R., Filippatos G., et al. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28 (2007) 230-268
34. Eddahibi S., Chaouat A., Morrell N., Fadel E., Fuhrman C., Bugnet A.S., et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108 (2003) 1839-1844
35. Thabut G., Dauriat G., Stern J.B., Logeart D., Lévy A., Marrash-Chahla R., et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127 (2005) 1531-1536
36. Chaouat A., Bugnet A.S., Kadaoui N., Schott R., Enache I., Ducolone A., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005) 189-194
37. Lettieri C.J., Nathan S.D., Barnett S.D., Ahmad S., and Shorr A.F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129 (2006) 746-752
38. Cottin V., Nunes H., Brillet P.Y., Delaval P., Devouassoux G., Tillie-Leblond I., et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26 (2005) 586-593
39. Pengo V., Lensing A.W., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 (2004) 2257-2264
40. Hoeper M.M., Mayer E., Simonneau G., and Rubin L.J. Chronic thromboembolic pulmonary hypertension. Circulation 113 (2006) 2011-2020
41. Bristow M.R., Minobe W., Rasmussen R., Larrabee P., Skerl L., Klein J.W., et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 89 (1992) 803-815
42. Keogh A., Benza R.L., Corris P., Dartevelle P., Frost A., Kim N.H., et al. Interventional and surgical modalities of treatment in pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009) S67-S77
43. Abraham W.T., Raynolds M.V., Gottschall B., Badesch D.B., Wynne K.M., Groves B.M., et al. Importance of angiotensinconverting enzyme in pulmonary hypertension. Cardiology 10 Suppl 1 (1995) 9-15
44. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
45. Gaine S.P., and Rubin L.J. Primary pulmonary hypertension. Lancet 352 (1998) 719-725
46. Tongers J., Schwerdtfeger B., Klein G., Kempf T., Schaefer A., Knapp J.M., et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 153 (2007) 127-132
47. Fisher M.R., Forfia P.R., Chamera E., Housten-Harris T., Champion H.C., Girgis R.E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Resp Crit Care Med 179 (2009) 615-621
48. McQuillan B.M., Picard M.H., Leavitt M., and Weyman A.E. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 104 (2001) 2797-2802
49. Sitbon O., Lascoux-Combe C., Delfraissy J.F., Yeni P.G., Raffi F., De Z.D., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177 (2008) 108-113
50. Mukerjee D., St George D., Knight C., Davar J., Wells A.U., Du Bois R.M., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 43 (2004) 461-466
51. Launay D., Mouthon L., Hachulla E., Pagnoux C., De Groote P., Remy-Jardin M., et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 34 (2007) 1005-1011
52. Grunig E., Weissmann S., Ehlken N., Fijalkowska A., Fischer C., Fourme T., et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 119 (2009) 1747-1757
53. Tunariu N., Gibbs S.J.R., Win Z., Gin-Sing W., Graham A., Gishen P., et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 48 (2007) 680-684
54. Resten A., Maitre S., Humbert M., Rabiller A., Sitbon O., Capron F., et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 183 (2004) 65-70
55. Dartevelle P., Fadel E., Mussot S., Chapelier A., Herve P., De Perrot M., et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 23 (2004) 637-648
56. Reichelt A., Hoeper M.M., Galanski M., and Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol 71 (2009) 49-54
57. Marcus J.T., Gan C.T., Zwanenburg J.J., Boonstra A., Allaart C.P., Götte M.J.W., et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol 51 (2008) 750-757
58. Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. Eur Heart J 28 (2007) 1187-1189
59. Rich S., Kieras K., Groves B., Stobo J.D., and Brundage B. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 8 (1986) 1307-1311
60. Chu J.W., Kao P.N., Faul J.L., and Doyle R.L. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 122 (2002) 1668-1673
61. Albrecht T., Blomley M.J., Cosgrove D.O., Taylor-Robinson S.D., Jayaram V., Eckersley R., et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 353 (1999) 1579-1583
62. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 133 (2003) 163-169
63. Hoeper M.M., Lee S.H., Voswinckel R., Palazzini M., Jais X., Marinelli A., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48 (2006) 2546-2552
64. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007) 2539-2550
65. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
66. Sitbon O., Humbert M., Jais X., Ioos V., Hamid A.M., Provencher S., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
67. Galiè N., Ussia G., Passarelli P., Parlangeli R., Branzi A., and Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 75 (1995) 55A-62A
68. McLaughlin V.V., Genthner D.E., Panella M.M., and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
69. McLaughlin V.V., Presberg K.W., Doyle R.L., Abman S.H., McCrory D.C., Fortin T., et al. Prognosis of pulmonary arterial hypertension ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 78S-92S
70. Eysmann S.B., Palevsky H.I., Reichek N., Hackney K., and Douglas P.S. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 80 (1989) 353-360
71. Raymond R.J., Hinderliter A.L., Willis P.W., Ralph D., Caldwell E.J., Williams W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39 (2002) 1214-1219
72. Tei C., Dujardin K.S., Hodge D.O., Bailey K.R., McGoon M.D., Tajik A.J., et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9 (1996) 838-847
73. Yeo T.C., Dujardin K.S., Tei C., Mahoney D.W., McGoon M.D., and Seward J.B. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81 (1998) 1157-1161
74. Forfia P.R., Fisher M.R., Mathai S.C., Housten-Harris T., Hemnes A.R., Borlaug B.A., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174 (2006) 1034-1041
75. Wensel R., Opitz C.F., Anker S.D., Winkler J., Hoffken G., Kleber F.X., et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106 (2002) 319-324
76. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) S40-S47
77. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
78. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
79. Sitbon O., Humbert M., Nunes H., Parent F., García G., Herve P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
80. Paciocco G., Martínez F., Bossone E., Pielsticker E., Gillespie B., and Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17 (2001) 647-652
81. Oudiz R.J., Barst R.J., Hansen J.E., Sun X.G., Garofano R., Wu X., et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 97 (2006) 123-126
82. Barst R.J., McGoon M., Mc Laughlin V.V., Tapson V., Rich S., Rubin L., et al., For the Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2125
83. Barst R.J., Langleben D., Frost A., Horn E.M., Oudiz R., Shapiro S., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
84. Ross R.M. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167 (2003) 1451
85. Palange P., Ward S.A., Carlsen K.H., Casaburi R., Gallagher C.G., Gosselink R., et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 29 (2007) 185-209
86. Voelkel M.A., Wynne K.M., Badesch D.B., Groves B.M., and Voelkel N.F. Hyperuricemia in severe pulmonary hypertension. Chest 117 (2000) 19-24
87. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
88. Williams M.H., Handler C.E., Akram R., Smith C.J., Das C., Smee J., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27 (2006) 1485-1494
89. Fijalkowska A., Kurzyna M., Torbicki A., Szewczyk G., Florczyk M., Pruszczyk P., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 (2006) 1313-1321
90. Andreassen A.K., Wergeland R., Simonsen S., Geiran O., Guevara C., and Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98 (2006) 525-529
91. Torbicki A., Kurzyna M., Kuca P., Fijalkowska A., Sikora J., Florczyk M., et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108 (2003) 844-848
92. Lankeit M., Dellas C., Panzenbock A., Skoro-Sajer N., Bonderman D., Olschewski M., et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J 31 (2008) 1024-1029
93. Nickel N., Kempf T., Tapken H., Tongers J., Laenger F., Lehmann U., et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178 (2008) 534-541
94. McLaughlin V.V., and McGoon M.D. Pulmonary arterial hypertension. Circulation 114 (2006) 1417-1431
95. Sitbon O., McLaughlin V.V., Badesch D.B., Barst R.J., Black C., Galiè N., et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60 (2005) 1025-1030
96. Sun X.G., Hansen J.E., Oudiz R., and Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 104 (2001) 429-435
97. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
98. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galiè N., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
99. Galiè N., Manes A., Negro L., Palazzini M., Bacchi Reggiani M.L., and Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30 (2009) 394-403
100. Loewe B., Graefe K., Ufer C., Kroenke K., Grünig E., Herzog W., et al. Anxiety and depression in patients with pulmonary hypertension. Psycosom Med 66 (2004) 831-836
101. Mereles D., Ehlken N., Kreuscher S., Ghofrani S., Hoeper M.M., Halank M., et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114 (2006) 1482-1489
102. The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 24 (2003) 761-781
103. Bedard E., Dimopoulos K., and Gatzoulis M.A. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?. Eur Heart J 30 (2009) 256-265
104. Thorne S., Nelson-Piercy C., MacGregor A., Gibbs S., Crowhurst J., Panay N., et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care 32 (2006) 75-81
105. Bendayan D., Hod M., Oron G., Sagie A., Eidelman L., Shitrit D., et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet Gynecol 106 (2005) 1206-1210
106. Bonnin M., Mercier F.J., Sitbon O., Roger-Christoph S., Jais X., Humbert M., et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anestesiology 102 (2005) 1133-1137
107. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., and Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
108. Herve P., Humbert M., Sitbon O., Parent F., Nunes H., Legal C., et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med 22 (2001) 451-458
109. Hoeper M.M., Sosada M., and Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 12 (1998) 1446-1449
110. Huber K., Beckmann R., Frank H., Kneussl M., Mlczoch J., and Binder B.R. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 150 (1994) 929-933
111. Sandoval J., Aguirre J.S., Pulido T., Martínez-Guerra M.L., Santos E., Alvarado P., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 164 (2001) 1682-1687
112. Weitzenblum E., Sautegeau A., Ehrhart M., Mammosser M., and Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 131 (1985) 493-498
113. Rich S., Seidlitz M., Dodin E., Osimani D., Judd D., Genthner D., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114 (1998) 787-792
114. Mukerjee D., St George D., Coleiro B., Knight C., Denton C.P., Davar J., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 (2003) 1088-1093
115. Jones D.A., Benjamin C.W., and Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 48 (1995) 890-896
116. Galiè N., Manes A., and Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2 (2003) 123-137
117. Rubin L.J., Mendoza J., Hood M., McGoon M., Barst R., Williams W.B., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112 (1990) 485-491
118. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
119. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
120. Rosenzweig E.B., Kerstein D., and Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99 (1999) 1858-1865
121. Krowka M.J., Frantz R.P., McGoon M.D., Severson C., Plevak D.J., and Wiesner R.H. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30 (1999) 641-648
122. Nunes H., Humbert M., Sitbon O., Morse J.H., Deng Z., Knowles J.A., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167 (2003) 1433-1439
123. Cabrol S., Souza R., Jais X., Fadel E., Ali R.H.S., Humbert M., et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 26 (2007) 357-362
124. Doran A.K., Ivy D.D., Barst R.J., Hill N., Murali S., and Benza R.L. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 160 (2008) 5-9
125. Olschewski H., Simonneau G., Galiè N., Higenbottam T., Naeije R., Rubin L.J., et al., For the AIR Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
126. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S., Channick R.N., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
127. Higenbottam T., Butt A.Y., McMahon A., Westerbeck R., and Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80 (1998) 151-155
128. Simonneau G., Barst R.J., Galiè N., Naeije R., Rich S., Bourge R.C., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
129. Barst R.J., Galiè N., Naeije R., Simonneau G., Jeffs R., Arneson C., et al. Longterm outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28 (2006) 1195-1203
130. Lang I., Gómez-Sánchez M., Kneussl M., Naeije R., Escribano P., Skoro-Sajer N., et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129 (2006) 1636-1643
131. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., Benza R.L., Widlitz A.C., Krichman A., et al. Safety and fficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-Week trial. Chest 129 (2006) 683-688
132. Sitbon O., Manes A., Jais X., Pallazini M., Humbert M., Presotto L., et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 49 (2007) 1-5
133. McLaughlin V., Rubin L., Benza R.L., Channick R., Vosswinkel R., Tapson V., et al. TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 177 (2009) A965
134. Galiè N., Humbert M., Vachiery J.L., Vizza C.D., Kneussl M., Manes A., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
135. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
136. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
137. Galiè N., Manes A., and Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61 (2004) 227-237
138. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
139. Rubin L.J., Badesch D.B., Barst R.J., Galiè N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
140. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galiè N., Boonstra A., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
141. Galiè N., Rubin L.J., Hoeper M., Jansa P., Al-Hiti H., Meyer G.M.B., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 371 (2008) 2093-2100
142. Galiè N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M.F., Lauer A., et al., For the Bosentan Randomized Trial of Endothelin Antagonist Therapy. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
143. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
144. Benza R.L., Barst R.J., Galiè N., Frost A., Girgis R.E., Highland K.B., et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a one year, prospective, open label, observation of outcome and survival. Chest 134 (2008) 775-782
145. Galiè N., Badesch B.D., Oudiz R., Simonneau G., McGoon M., Keogh A., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535
146. Galiè N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117 (2008) 3010-3019
147. McGoon M., Frost A., Oudiz R., Badesch B.D., Galiè N., Olschewski H., et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 135 (2009) 122-129
148. Wharton J., Strange J.W., Moller G.M.O., Growcott E.J., Ren X., Franklyn A.P., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172 (2005) 105-113
149. Tantini B., Manes A., Fiumana E., Pignatti C., Guarnieri G., Zannoli R., et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100 (2005) 131-138
150. Ghofrani H.A., Voswinckel R., Reichenberger F., Olschewski H., Haredza P., Karadas B., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44 (2004) 1488-1496
151. Bhatia S., Frantz R.P., Severson C.J., Durst L.A., and McGoon M.D. Immediate and longterm hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78 (2003) 1207-1213
152. Michelakis E.D., Tymchak W., Noga M., Webster L., Wu X.C., Lien D., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108 (2003) 2066-2069
153. Ghofrani H.A., Schermuly R.T., Rose F., Wiedemann R., Kohstall M.G., Kreckel A., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167 (2003) 1139-1141
154. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al., The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
155. Badesch D.B., Hill N.S., Burgess G., Rubin L.J., Barst R.J., Galiè N., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34 (2007) 2417-2422
156. Simonneau G., Rubin L., Galiè N., Barst R.J., Fleming T., Frost A., et al., For the Pulmonary Arterial Hypertension combination Study of Epoprostenol and Sildenafil (PACES) Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 149 (2008) 521-530
157. Galiè N., Brundage B., Ghofrani A., Oudiz R., Simonneau G., Safdar Z., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119 (2009) 2894-2903
158. Ghofrani H.A., Rose F., Schermuly R.T., Olschewski H., Wiedemann R., Kreckel A., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42 (2003) 158-164
159. Hoeper M.M., Faulenbach C., Golpon H., Winkler J., Welte T., and Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24 (2004) 1007-1010
160. Hoeper M., Taha N., Bekjarova A., and Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving non-parenteral prostanoids. Eur Respir J 22 (2003) 330-334
161. Mathai S.C., Girgis R.E., Fisher M.R., Champion H.C., Housten-Harris T., Zaiman A., et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 29 (2007) 469-475
162. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., and Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 (2005) 858-863
163. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S., Channick R.N., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
164. Hoeper M., Leuchte H., Halank M., Wilkens H., Meyer F.J., Seyfarth H.J., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 4 (2006) 691-694
165. Paul G.A., Gibbs J.S., Boobis A.R., Abbas A., and Wilkins M.R. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 60 (2005) 107-112
166. Humbert M., Segal E.S., Kiely D.G., Carlsen J., Schwierin B., and Hoeper M.M. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30 (2007) 338-344
167. Wrishko R.E., Dingemanse J., Yu A., Darstein C., Phillips D.L., and Mitchell M.I. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 48 (2008) 610-618
168. Hoeper M.M., Galiè N., Murali S., Olschewski H., Rubenfire M., Robbins I.M., et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 165 (2002) 341-344
169. Rozkovec A., Montanes P., and Oakley C.M. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J 55 (1986) 449-458
170. Sandoval J., Gaspar J., Pulido T., Bautista E., Martínez Guerra M.L., Zeballos M., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32 (1998) 297-304
171. Kurzyna M., Dabrowski M., Bielecki D., Fijalkowska A., Pruszczyk P., Opolski G., et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 131 (2007) 977-983
172. Althoff T.F., Knebel F., Panda A., McArdle J., Gliech V., Franke I., et al. Long-term follow-up of a fenestrated Amplatzer atrial septal occlude in pulmonary arterial hypertension. Chest 133 (2008) 283-285
173. Orens J.B., Estenne M., Arcasoy S., Conte J.V., Corris P., Egan J.J., et al., Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25 (2006) 745-755
174. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., Hertz M.I., and International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty third official adult lung and heart lung transplantation report-2006. J Heart Lung Transplant 25 (2006) 880-892
175. Waddell T.K., Bennett L., Kennedy R., Todd T.R., and Keshavjee S.H. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 21 (2002) 731-737
176. Barst R.J., Gibbs J.S., Ghofrani H.A., Hoeper M.M., McLaughlin V.V., Rubin L.J., et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009) S78-S84
177. Committee for Practice Guidelines (CPG) of the European Society of Cardiology. Recommendations for Task Force Creation and Report Production. A document for Task Force members and expert panels responsible for the creation and production of Guidelines and Expert Consensus Documents Committee for Practice Guidelines (CPG) of the European Society of Cardiology. European Society of Cardiology Website. Disponible en: http://www.escardio.org/scinfo/Recommendations.pdf
178. Konduri G.G. New approaches for persistent pulmonary hypertension of newborn. Clin Perinatol 31 (2004) 591-611
179. Rosenzweig E.B., Widlitz A., and Barst R. Pulmonary arterial hypertension in children. Pediatr Pulmon 38 (2004) 2-22
180. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart. 2008;94:i1-41.
181. Barst R., Ivy D., Widlitz A.C., Moore K., Doran A., Nguyen N., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73 (2003) 372-382
182. Rosenzweig E.B., Ivy D.D., Widlitz A., Doran A., Claussen L.R., Yung D., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 697-704
183. Humpl T., Reyes J.T., Holtby H., Stephens D., and Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111 (2005) 3274-3280
184. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
185. Lammers A.E., Hislop A.A., Flynn Y., and Haworth S.G. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 93 (2007) 739-743
186. Ivy D.D., Doran A.K., Smith K.J., Mallory Jr. G.B., Beghetti M., Barst R.J., et al. Short-and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51 (2008) 161-169
187. Micheletti A., Hislop A.A., Lammers A., Bonhoeffer P., Derrick G., Rees P., et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart 92 (2006) 969-972
188. Blanc J., Vouhe P., and Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med 350 (2004) 623
189. Engelfriet P.M., Duffels M.G.J., Moller T., Boersma E., Tijssen J.G.P., Thaulow E., et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 93 (2007) 682-687
190. Beghetti M., and Galiè N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 53 (2009) 733-740
191. Daliento L., Somerville J., Presbitero P., Menti L., Brach-Prever S., Rizzoli G., et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 19 (1998) 1845-1855
192. Hopkins W.E., Ochoa L.L., Richardson G.W., and Trulock E.P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15 (1996) 100-105
193. Diller G.P., and Gatzoulis M.A. Pulmonary vascular disease in adults with congenital heart disease. Circulation 115 (2007) 1039-1050
194. Hopkins W.E. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 16 (2005) 19-25
195. Broberg C.S., Ujita M., Prasad S., Li W., Rubens M., Bax B.E., et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 50 (2007) 634-642
196. Gatzoulis M.A., Beghetti M., Galiè N., Granton J., Berger R.M.F., Lauer A., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 127 (2007) 27-32
197. Palazzini M., Manes A., Romanazzi S., Gambetti S., Leci E., Grossi M., et al. Effects of sildenafil treatment in patients with pulmonary hypertension associated with congenital cardiac shunts. Eur Heart J 28 (2007) 308
198. Mukhopadhyay S., Sharma M., Ramakrishnan S., Yusuf J., Gupta M.D., Bhamri N., et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 114 (2006) 1807-1810
199. Dorfmuller P., Humbert M., Perros F., Sánchez O., Simonneau G., Muller K.M., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38 (2007) 893-902
200. Kawut S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., and Kimmel S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123 (2003) 344-350
201. Jais X., Launay D., Yaici A., Le P.J., Tcherakian C., Sitbon O., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 58 (2008) 521-531
202. Girgis R.E., Frost A.E., Hill N.S., Horn E.M., Langleben D., McLaughlin V.V., et al. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 66 (2007) 1467-1472
203. Oudiz R.J., Schilz R.J., Barst R.J., Galie N., Rich S., Rubin L.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126 (2004) 420-427
204. Herve P., Lebrec D., Brenot F., Simonneau G., Humbert M., Sitbon O., et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 11 (1998) 1153-1166
205. Hoeper M.M., Krowka M.J., and Strassburg C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 363 (2004) 1461-1468
206. Krowka M.J., Swanson K.L., Frantz R.P., McGoon M.D., and Wiesner R.H. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 44 (2006) 1502-1510
207. Provencher S., Herve P., Jais X., Lebrec D., Humbert M., Simonneau G., et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130 (2006) 120-126
208. Hoeper M.M., Halank M., Marx C., Hoeffken G., Seyfarth H.J., Schauer J., et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 25 (2005) 502-508
209. Reichenberger F., Voswinckel R., Steveling E., Enke B., Kreckel A., Olschewski H., et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 28 (2006) 563-567
210. Kuo P.C., Johnson L.B., Plotkin J.S., Howell C.D., Bartlett S.T., and Rubin L.J. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63 (1997) 604-606
211. Hoeper M.M., Seyfarth H.J., Hoeffken G., Wirtz H., Spiekerkoetter E., Pletz M.W., et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 30 (2007) 1096-1102
212. Krowka M.J., Plevak D.J., Findlay J.Y., Rosen C.B., Wiesner R.H., and Krom R.A. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 6 (2000) 443-450
213. Grannas G., Neipp M., Hoeper M.M., Gottlieb J., Luck R., Becker T., et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation 85 (2008) 524-531
214. Opravil M., Peche're M., Speich R., Joller Jemelka H.I., Jenni R., Russi E.W., et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155 (1997) 990-995
215. Cea-Calvo L., Escribano Subias P., Tello de Menesses R., Lázaro Salvador M., Gómez Sánchez M.A., Delgado Jiménez J.F., et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 56 (2003) 421-425
216. Ghofrani H.A., Friese G., Discher T., Olschewski H., Schermuly R.T., Weissmann N., et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 23 (2004) 321-326
217. Sitbon O., Gressin V., Speich R., Macdonald P.S., Opravil M., Cooper D.A., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 (2004) 1212-1217
218. Barbaro G., Lucchini A., Pellicelli A.M., Grisorio B., Giancaspro G., and Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 92 (2006) 1164-1166
219. Holcomb Jr. B.W., Loyd J.E., Ely E.W., Johnson J., and Robbins I.M. Pulmonary veno-occlusive disease: a case series and new observations. Chest 118 (2000) 1671-1679
220. Runo J.R., Vnencak-Jones C.L., Prince M., Loyd J.E., Wheeler L., Robbins I.M., et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 167 (2003) 889-894
221. Mandel J., Mark E.J., and Hales C.A. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 162 (2000) 1964-1973
222. Rabiller A., Jais X., Hamid A., Resten A., Parent F., Haque R., et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 27 (2006) 108-113
223. Montani D., Price L.C., Dorfmuller P., Achouh L., Jaïs X., Yaïci A., et al. Pulmonary veno-occlusive disease. Eur Respir J 33 (2009) 189-200
224. Humbert M., Maître S., Capron F., Rain B., Musset D., and Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 157 (1998) 1681-1685
225. Grigioni F., Potena L., Galiè N., Fallani F., Bigliardi M., Coccolo F., et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 25 (2006) 1241-1246
226. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al, ESC Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
227. Hoeper M., Barbera J.A., Channick R., Hassoun P.M., Lang I., Manes A., et al. Diagnosis, assessment, and treatment of non-PAH pulmonary hypertension. J Am Coll Cardiol 54 (2009) S85-S96
228. Aurigemma G.P., and Gaasch W.H. Clinical practice. Diastolic heart failure. N Engl J Med 351 (2004) 1097-1105
229. Costanzo M.R., Augustine S., Bourge R., Bristow M., O'Connell J.B., Driscoll D., et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 92 (1995) 3593-3612
230. Chang P.P., Longenecker J.C., Wang N.Y., Baughman K.L., Conte J.V., Hare J.M., et al. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant 24 (2005) 998-1007
231. Costard-Jackle A., and Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19 (1992) 48-54
232. Califf R.M., Adams K.F., McKenna W.J., Gheorghiade M., Uretsky B.F., McNulty S.E., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
233. Packer M., McMurray J., Massie B.M., Caspi A., Charlon V., Cohen-Solal A., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11 (2005) 12-20
234. Kalra P.R., Moon J.C., and Coats A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol 85 (2002) 195-197
235. Lewis G.D., Shah R., Shahzad K., Camuso J.M., Pappagianopoulos P.P., Hung J., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007) 1555-1562
236. Roques F., Nashef S.A., Michel P., Gauducheau E., De Vincentiis C., Baudet E., et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15 (1999) 816-822
237. Oswald-Mammosser M., Weitzenblum E., Quoix E., Moser G., Chaouat A., Charpentier C., et al. Prognostic factors in COPD patients receiving longterm oxygen therapy. Importance of pulmonary artery pressure. Chest 107 (1995) 1193-1198
238. Kessler R., Faller M., Fourgaut G., Mennecier B., and Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159 (1999) 158-164
239. Arcasoy S.M., Christie J.D., Ferrari V.A., St John S.M., Zisman D.A., Blumenthal N.P., et al. Echocardiographic assessment of pulmonary hypertension in patients with advance lung disease. Am J Respir Crit Care Med 167 (2003) 735-740
240. Fisher M.R., Criner G.J., Fishman A.P., Hassoun P.M., Minai O.A., Scharf S.M., et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 30 (2007) 914-921
241. Agusti A.G., Barbera J.A., Roca J., Wagner P.D., Guitart R., and Rodríguez-Roisin R. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 97 (1990) 268-275
242. Barbera J.A., Roger N., Roca J., Rovira I., Higenbottam T.W., and Rodríguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronicobstructive pulmonary disease. Lancet 347 (1996) 436-440
243. Morrell N.W., Higham M.A., Phillips P.G., Shakur B.H., Robinson P.J., and Beddoes R.J. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res 6 (2005) 88-95
244. Saadjian A.Y., Philip-Joet F.F., Vestri R., and Arnaud A.G. Long-term treatment of chronic obstructive lung disease by nifedipine: an 18-month haemodynamic study. Eur Respir J 1 (1988) 716-720
245. Ghofrani H.A., Wiedemann R., Rose F., Schermuly R.T., Olschewski H., Weissmann N., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
246. Olschewski H., Ghofrani H.A., Walmrath D., Schermuly R., Temmesfeld-Wollbruck B., Grimminger F., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160 (1999) 600-607
247. Alp S., Skrygan M., Schmidt W.E., and Bastian A. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther 19 (2006) 386-390
248. Collard H.R., Anstrom K.J., Schwarz M.I., and Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131 (2007) 897-899
249. Gunther A., Enke B., Markart P., Hammerl P., Morr H., Behr J., et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 29 (2007) 713-719
250. Madden B.P., Allenby M., Loke T.K., and Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 44 (2006) 372-376
251. Rietema H., Holverda S., Bogaard H.J., Marcus J.T., Smit H.J., Westerhof N., et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 31 (2008) 759-764
252. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galie N., Pruszczyk P., et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29 (2008) 2276-2315
253. Rubin L.J., Hoeper M.M., Klepetko W., Galie N., Lang I.M., and Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc 3 (2006) 601-607
254. Bonderman D., Wilkens H., Wakounig S., Schafers H.J., Jansa P., Lindner J., et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 33 (2009) 325-331
255. Bresser P., Fedullo P.F., Auger W.R., Channick R.N., Robbins I.M., Kerr K.M., et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 23 (2004) 595-600
256. Nagaya N., Sasaki N., Ando M., Ogino H., Sakamaki F., Kyotani S., et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 123 (2003) 338-343
257. Hoeper M.M., Kramm T., Wilkens H., Schulze C., Schafers H.J., Welte T., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2363-2367
258. Hughes R., George P., Parameshwar J., Cafferty F., Dunning J., Morrell N.W., et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 60 (2005) 707
259. Bonderman D., Nowotny R., Skoro-Sajer N., Jakowitsch J., Adlbrecht C., Klepetko W., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2599-2603
260. Reichenberger F., Voswinckel R., Enke B., Rutsch M., Fechtali E.E., Schmehl T., et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 30 (2007) 922-927
261. Jais X., D'Armini A.M., Jansa P., Torbicki A., Delcroix M., Ghofrani H.A., et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebocontrolled trial. J Am Coll Cardiol 52 (2008) 2127-2134